Clinical trials
Oral Potentially Malignant Disorders clinical trials
Below are recruiting oral potentially malignant disorders clinical trials, each written for real people, not researchers. We’re tracking 19 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06535867Recruiting
Comparing phone-based vs. in-person mouth cancer screening in rural India
This study compares two ways to find early signs of mouth cancer or conditions that could lead to cancer. One method uses a simple phone-based health check, and the other uses standard in-person screening. People in rural areas of Varanasi who are at risk—such as those who use tobacco or have mouth sores—may be able to join.
New York, New YorkAges 18 years+ - NCT04584333Recruiting
Dentist care for alcohol-related mouth changes
This trial looks at whether a dentist-led approach can help control ongoing mouth conditions linked with heavy alcohol use. It focuses on adults with long-lasting mouth patches diagnosed by biopsy as oral lichen planus or oral leukoplakia.
Santiago de Compostela, A CoruñaAges 40 years+ - NCT05562375Recruiting
Testing a device to detect early mouth pre-cancer changes
This study checks whether a handheld device (GOCCLES®) can spot early mouth “pre-cancer” changes by looking at suspicious areas in the mouth. If it works, it could help doctors find these problems earlier and guide next steps.
Alcorcón, MadridAges 18 years+ - NCT05853783Recruiting
Testing a mouth test on biopsy samples from abnormal lesions
This trial looks at archived (saved) mouth biopsy samples to see how well the STRATICYTE™ test can identify potentially dangerous “pre-cancer-like” changes. It may help doctors screen or better understand which abnormal areas in the mouth later turn into oral cancer.
Birmingham, AlabamaAges 18 years+ - NCT06321003Recruiting
Testing AI to detect early oral cancer with light scans
This trial uses a special light-based scanner (OCT) and artificial intelligence to help diagnose early signs of mouth cancer or precancer. It aims to see if this combination can make diagnosis easier and more accurate.
PalermoAges 18–99 - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05207085RecruitingPhase 2
Testing valbenazine for adult hair-pulling disorder symptoms
This Phase 2 study tests whether valbenazine can reduce symptoms of trichotillomania (a hair-pulling disorder) in adults. You may be able to join if your symptoms cause major distress or interfere with daily life.
New Haven, ConnecticutAges 18–65 - NCT05891379Recruiting
Inebilizumab for adults with acute neuromyelitis optica attacks
This trial studies inebilizumab to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are having an acute attack. It aims to reduce ongoing nerve damage and disability after a recent flare, alongside standard steroid treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04079179RecruitingPhase 2
Cobimetinib for difficult Langerhans cell and similar disorders
This Phase 2 trial studies cobimetinib, a medicine that targets a specific growth-and-signal pathway, to treat stubborn (refractory or worsening) Langerhans cell histiocytosis and related disorders. It may help shrink active disease or stop disease from progressing.
Phoenix, ArizonaAges Any age - NCT05876182RecruitingPhase 2
Vancomycin for primary sclerosing cholangitis
This Phase 2 study tests whether the antibiotic vancomycin can improve primary sclerosing cholangitis (PSC), a long-term bile-duct disease. You may be eligible if you have confirmed PSC and certain blood test and safety criteria, and you can follow medication washout rules.
Monza, Monza E BrianzaAges 15–70 - NCT06275919RecruitingPhase 2
Regorafenib for recurring meningioma
This trial tests a pill called regorafenib for people whose meningioma (a brain tumor) has come back and cannot be treated with surgery or radiation. The goal is to see if regorafenib can help stop the tumor from growing further.
Meldola, Forlì-CesenaAges 18 years+ - NCT07541781RecruitingPhase 1
Sitagliptin for recurrent grade 4 glioma
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Iowa City, IowaAges 18 years+ - NCT07151378RecruitingPhase 3
Intestinal gel for Parkinson's mood and behavior problems
This trial tests a gel form of levodopa (called Lecigon) given through a tube into the intestine to see if it helps reduce mood swings, impulsive behaviors, and other mental side effects in people with Parkinson's who already have motor fluctuations. It is for people who have had Parkinson's for at least 5 years and are between 18 and 75 years old.
Saarlouis, SaarlandAges 18–75 - NCT07741071RecruitingPhase 2
Vitamin B3 supplement for early Alzheimer's disease
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
BergenAges 50–85 - NCT06847399RecruitingPhase 2
Tirzepatide for Binge Eating Disorder
This trial tests if tirzepatide (a weekly injection) can help reduce binge eating compared to a placebo or another medication (lisdexamfetamine dimesylate). It may be a good fit for people with moderate or severe binge eating disorder who also have a high body weight.
Baltimore, MarylandAges 18 years+ - NCT06136884RecruitingPhase 1
Study of AO-252 for advanced solid tumors with or without brain metastases
This trial tests an experimental oral pill (AO-252) that targets a protein called TACC3 in advanced solid tumors, including those that have spread to the brain. It is for people whose cancer has a specific genetic change (TP53 mutation) or who have prostate cancer, and who have already tried other treatments.
Detroit, MichiganAges 18 years+
Hear when a new Oral Potentially Malignant Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oral potentially malignant disorders?
- Yes. Clin2 currently lists 19 recruiting oral potentially malignant disorders studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oral potentially malignant disorders trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oral potentially malignant disorders trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.